Kiadis Pharma NV has appointed Jan Feijen as chief operations officer to help the cell therapy company set up and run a commercial supply chain as its lead product moves into Phase 3 development.
Mr Feijen joins Kiadis from Janssen (Johnson & Johnson Inc) where he was head of manufacturing and technical operations for vaccines and advanced therapies. Kiadis’ lead product is an adjunctive treatment to a haematopoietic stem cell transplantation which is designed to fight infections while stem cells from the graft are growing.
Kiadis announced the appointment on 20 March 2017
Copyright 2017 Evernow Publishing Ltd